Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.43

+3.8%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$159.68M
EPS-1.6700
P/E Ratio-4.45
Earnings Date08/13/2026

uncy

Other Financing Activities

Last Annual Value

-1.61M

3-Year CAGR

-49%

5-Year CAGR

-69%

10-Year CAGR

-12%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of Other Financing Activities

UNCY · NASDAQ
CompanyOther Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
-1.61M
N/AN/AN/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-199.00K
N/AN/AN/A
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
-142.00K
N/AN/AN/A
-360.00K
N/AN/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
69.00
N/A-88.3%N/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
54.63M
11.8%148.0%N/A
-65.00K
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
-750.00K
N/AN/AN/A
0.00
N/AN/AN/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.43, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.43